Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1984;70:271-278

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sharpe, D. N.
Right arrow Articles by Hannan, S. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sharpe, D. N.
Right arrow Articles by Hannan, S. F.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ENALAPRIL MALEATE
Medline Plus Health Information
*Heart Failure

Circulation, Vol 70, 271-278, Copyright © 1984 by American Heart Association


ARTICLES

Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study

DN Sharpe, J Murphy, R Coxon and SF Hannan

A number of studies have shown short-term hemodynamic and symptomatic improvement in patients with congestive heart failure treated with angiotensin converting-enzyme inhibitors. The long-term efficacy of the oral long-acting converting-enzyme inhibitor enalapril remains to be established in controlled studies. We evaluated this drug in 36 patients with New York Heart Association functional class II to III heart failure who were clinically stable on digoxin and diuretic therapy. After baseline assessment of symptoms, exercise capacity, and results of echocardiographic examination and right heart catheterization, patients were randomly assigned to treatment with 5 mg enalapril twice daily (n = 18) or placebo (n = 18) in a double-blind fashion. The two groups had similar clinical, echocardiographic, and hemodynamic characteristics before treatment. After 3 months of treatment, the enalapril group showed a significant improvement as judged by subjective patient impression, functional class, and exercise duration (9.3 +/- 5.7 vs 17.6 +/- 5.6 min; p less than .001). Diuretic dosage was reduced in six patients and increased in one patient, one patient had died and another had been withdrawn from the study. In the placebo group there was no significant change with respect to patient impression, functional class, or exercise duration; diuretic dosage was increased in seven patients and four patients had died. Echocardiographic left ventricular dimensions were significantly reduced and left ventricular shortening fraction significantly increased in the enalapril group but were unchanged in the placebo group.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
CirculationHome page
A. Dore, C. Houde, K.-L. Chan, A. Ducharme, P. Khairy, M. Juneau, F. Marcotte, and L.-A. Mercier
Angiotensin Receptor Blockade and Exercise Capacity in Adults With Systemic Right Ventricles: A Multicenter, Randomized, Placebo-Controlled Clinical Trial
Circulation, October 18, 2005; 112(16): 2411 - 2416.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
Developed in Collaboration With the American Colle, Endorsed by the Heart Rhythm Society, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, et al.
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure)
J. Am. Coll. Cardiol., September 20, 2005; 46(6): 1116 - 1143.
[Full Text] [PDF]


Home page
CirculationHome page
S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al.
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society
Circulation, September 20, 2005; 112(12): 1825 - 1852.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. Adler, E. Messina, B. Sherman, Z. Wang, H. Huang, A. Linke, and T. H. Hintze
NAD(P)H oxidase-generated superoxide anion accounts for reduced control of myocardial O2 consumption by NO in old Fischer 344 rats
Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H1015 - H1022.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
A. H. Jamali, W. H. W. Tang, U. N. Khot, and M. B. Fowler
The Role of Angiotensin Receptor Blockers in the Management of Chronic Heart Failure
Arch Intern Med, March 12, 2001; 161(5): 667 - 672.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. N. Nanas, G. Alexopoulos, M. I. Anastasiou-Nana, K. Karidis, A. Tirologos, S. Zobolos, V. Pirgakis, L. Anthopoulos, D. Sideris, S. F. Stamatelopoulos, et al.
Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study
J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2090 - 2095.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
P. R. Forfia, X. Zhang, D. R. Knight, A. H. Smith, C. P. A. Doe, E. A. Wolfgang, D. M. Flynn, M. S. Wolin, and T. H. Hintze
NO modulates myocardial O2 consumption in the nonhuman primate: an additional mechanism of action of amlodipine
Am J Physiol Heart Circ Physiol, June 1, 1999; 276(6): H2069 - H2075.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
W. T. Abraham
Pharmacologic Management of Chronic Heart Failure: A Review
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 1998; 2(3): 168 - 190.
[Abstract] [PDF]


Home page
CirculationHome page
Effects of Carvedilol, a Vasodilator–ß-Blocker, in Patients With Congestive Heart Failure Due to Ischemic Heart Disease
Circulation, July 15, 1995; 92(2): 212 - 218.
[Abstract] [Full Text]


Home page
Journal of Pharmacy PracticeHome page
M. A. Munger, S. F. Gardner, and R. C. Jarvis
Endocrinologic Warfare: The Role of Angiotensin-Converting Enzyme Inhibitors in Congestive Heart Failure
Journal of Pharmacy Practice, January 1, 1990; 3(5): 318 - 331.
[Abstract] [PDF]